Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PolyDamas: amivantamab + cetrelimab in metastatic non-small cell lung cancer
2022-501452-29-00Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, open-label trial of amivantamab and cetrelimab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Incidence and severity of adverse events including dose-limiting toxicities and Objective response rate. Started Aug 2024; status: completed.
02
Drugs
amivantamabcetrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-501452-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501452-29-00.